Many treatments are sold to relieve the symptoms of degenerative joint disease. However, not all products are supported by solid scientific research or manufactured under approval by the U.S. Food and Drug Administration. Those include injectable chondroitin sulfate, pharmacy-compounded injectable glucosamine, and oral products claiming to be sulfated glycosaminoglycans. Studies of non-FDA approved products and oral nutritional supplements have shown significantly less effectiveness than products with FDA approval. Generic products also require FDA approval since generic drugs are chemical copies of approved drugs that no longer have patent protection. No approved generic forms of Adequan® i.m. (polysulfated glycosaminoglycan) are currently available. See product insert for full product information.
Ask your veterinarian for FDA-approved Adequan® i.m. (polysulfated glycosaminoglycan)
Early recognition and treatment can limit the damage and restore the normal “wear and repair” balance in the joints before permanent cartilage or bone damage occurs. Non-infectious arthritis, also known as degenerative joint disease, is estimated to cause one-third of all lameness cases. Adequan® i.m. (polysulfated glycosaminoglycan) is the only disease-modifying osteoarthritis drug on the market approved by the FDA for the treatment of equine arthritis. It is the only joint therapy clinically proven to relieve symptoms and treat the underlying causes of equine degenerative joint disease.
After six weeks of comparison to intravenous Legend® (intravenous sodium hyaluronate), Adequan® i.m. demonstrated, on average, a more rapid and significantly better recovery:
Equine therapies are not created equal.
